A Comprehensive Self-Management Intervention for individuals with Inflammatory Bowel Disease

NIH RePORTER · NIH · K23 · $143,378 · view on reporter.nih.gov ↗

Abstract

PROJECT SUMMARY/ABSTRACT Individuals with inflammatory bowel disease (IBD) experience a high burden of symptoms including abdominal pain, bloating, fatigue, sleep disturbances, anxiety, and depression. Yet, few self-management interventions exist to reduce symptoms in this population. This proposed study will adapt an existing Comprehensive Self- Management Intervention (CSM) with demonstrated efficacy in an irritable bowel syndrome population into a population of individuals with IBD (CSM-IBD). The long-term training goal of this project is to assist Dr. Kamp in becoming an independent investigator with a program of research focused on improving self- and symptom- management among individuals with IBD. As such, Dr. Kamp has training competencies to increase knowledge and skills in advanced training in conducting randomized controlled trials, longitudinal data management, processing and analysis of microbiome data and leading interdisciplinary teams. The Specific Aims are to: 1) determine the feasibility and acceptability of study procedures (recruitment, randomization, data and sample collection) and the CSM-IBD; 2) compare the CSM-IBD intervention to usual care on changes from baseline to 3 months post-intervention in quality of life and daily symptoms (fatigue, sleep disturbance, psychological distress, and GI symptoms); and 3) explore the association of symptoms with socioecological factors (age, sex, race/ethnicity, diet), clinical phenotype (medications, disease distribution), and biological signatures (microbiome, calprotectin) with symptoms at baseline and response to intervention (immediately post- intervention). The expected outcome will be preliminary feasibility data to inform a future R01 study which will examine the efficacy of the CSM-IBD. To accomplish the research aims and training goals, an interdisciplinary mentorship team has been assembled with expertise in symptom science, IBD, psychology, interdisciplinary research, RCTs, gut microbiome, statistics, and data management. The team, along with the vast array of resources available at the University of Washington, are well-suited to transition Dr. Kamp into an independent investigator. This research is significant because it will address an unmet need regarding self-management among individuals with IBD and has the potential to not only significantly improve the quality of life but also change the clinical management paradigm for individuals with IBD.

Key facts

NIH application ID
10447396
Project number
1K23NR020044-01A1
Recipient
UNIVERSITY OF WASHINGTON
Principal Investigator
Kendra Joy Kamp
Activity code
K23
Funding institute
NIH
Fiscal year
2022
Award amount
$143,378
Award type
1
Project period
2022-04-12 → 2025-03-31